On August 4, Certara (NASDAQ:CERT) reported second-quarter 2026 results that told two different stories at once. Software revenue climbed 4% to $48.8 million, and bookings for that segment jumped 9%, yet the company swung to a $6.1 million net loss just a year after posting a small profit. Layered on top of a completed divestiture, a workforce reduction, and a fresh executive shuffle, the quarter reads like a company mid-transformation rather than one settling into a steady rhythm.
Software Carries The Business Forward
Certara’s software business is where the momentum lives. Q2 software revenue rose 4% year over year to $48.8 million, and software bookings jumped 9% to $50.7 million, the strongest signal in the report that customers are still committing new spend. Total revenue reached $93.3 million, up 1% from $92.4 million a year earlier, with management reaffirming full-year revenue guidance of $367 million to $382 million, or growth of 0% to 4%. CEO Jon Resnick described the quarter as part of an effort to build a company that can deliver sustainable double-digit growth, pointing toward the two business units, Model Informed Discovery and Drug Development and Accelerated Clinical Evidence, that Certara stood up in May after closing the sale of its Regulatory and Medical Writing business on May 8.
Certara backed that restructuring with real cost discipline. The reduction in force completed during the quarter, which touched about 5% of the global workforce, is expected to generate roughly $13 million in annualized savings, aimed squarely at overhead and stranded costs left over from the divestiture. The balance sheet also strengthened, with cash and equivalents rising to $184.1 million from $162.3 million a year earlier. In the second quarter, Certara spent $17.4 million to complete its $100 million share repurchase program, and in the third quarter the board approved an additional $50 million for buybacks, a decision the company tied to confidence in its underlying business. New Chief Commercial Officer Julien Perrier, who joined effective August 1, 2026, after leading commercial strategy at Ziwig and holding senior roles at IQVIA, AbbVie, and Sanofi, is now tasked with sharpening that go-to-market execution.
Where The Losses Crept In
The services side of the business told the opposite story. Services revenue fell 3% to $44.5 million, and services bookings dropped 6% to $47.6 million, both decelerating from the prior year. That weakness, combined with higher costs, pushed Certara to a net loss of $6.1 million in the quarter, compared with net income of $1.5 million a year earlier, a swing the company attributed largely to the absence of a $5.7 million favorable contingent consideration adjustment that had flattered the prior-year period. Diluted loss per share came in at $0.04, reversing the $0.01 EPS Certara earned in the second quarter of 2025.
Profitability metrics moved in the same direction. Adjusted EBITDA fell 3% to $26.2 million from $27.0 million, and total operating expenses climbed to $58.3 million from $50.4 million, an increase of $7.9 million driven partly by that contingent consideration remeasurement and partly by higher professional, consulting, and executive recruiting costs. Interim CFO Faiz Mohammed acknowledged the second half still carries the weight of the full-year plan, reaffirming guidance of 0% to 4% revenue growth rather than raising it. For a company mid-restructuring, that guidance leaves little room for further softness in services.
What The Market Is Pricing In
Hedge fund ownership of Certara fell from 36 funds to 27 funds quarter over quarter, a pullback that lines up with the earnings swing to a net loss. Short interest sits at 29.75% of the float, a level that signals heavy organized skepticism toward the stock. Yet the forward price-to-earnings ratio is just 12.67, as of September 11, a multiple that assumes very little growth is coming. That combination sets up a stock where sentiment and valuation are pulling in opposite directions.
The Turnaround Is Still Unproven
Certara’s second quarter is a snapshot of a company reshaping itself while still meeting its numbers. Software growth, completed cost cuts, and a larger buyback authorization all point to a restructuring that is starting to take hold. But the net loss, the services slowdown, and guidance that was reaffirmed rather than raised show the transformation still carries real costs on the income statement. The open question is whether software bookings keep growing fast enough to outrun the drag from services and one-time restructuring charges.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
